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A 66 year-old Caucasian patient presented to our attention 
complaining for an heliotrope rash and  large diffuse erythematous 
itching with pustular-like lesions on his trunk, upper arms, involving 
the upper gluteus, with a yellowish necrotic like surface (Figure 
1A,1B).  Brown-to-purple lesions were also present on the right side of 
his back associated to muscle weakness. His personal medical history 
was positive for diabetes, hypertension and a 14 months history of 
squamous cell carcinoma of the lung. After 45 days of a sequential 
chemotherapic combination, with carboplatin/gemcitabine/taxotere/
bevacizumab regimen the patient referred the onset of the skin reaction.
Laboratory investigations showed red blood cells 3.6 X103 uL 
(4.52-5.10 X 103 uL), hemoglobin 11.6 g/dL(14-18 g/dL), haematocrit 
34.4%( 42-50 %), MCV 16.2% femtolitre  (80-96 femtolitre), white 
cells 10.9X103 uL (4-8.500/mm3) with neutrophilia, ferritin 931 ng/
mL(20-300 ng/ml), LDH 480 U/L(122-222 U/L) and Potassium 5.4 
g/dL (3.5-5.1 mEq/L). While the remaining laboratory investigations 
(including renal function, hepatic functions, autoantibody, calcium 
and phosphorous) were between normal ranges, as well as a chest 
X-Ray. The patient also showed an increased body temperature
(maximum reached: 38°C), which disappeared after the administration
of an intra-venous antibiotic therapy, with normalization of the
laboratory tests. A cutaneous biopsy from the arm showed perivascular 
inflammatory cells in the dermis with increased dermal mucin, and
atrophic epidermis with vacuolar basal changes and myofiber necrosis
(Figure 2A,2B). According to the clinical and pathological findings, a
final diagnosis of dermatomyositis with calciphylaxis aspect was made. 
The patient underwent to a steroidal immunosuppressive treatment
(prednisolone 40 mg/day), with a fast response. However 6 weeks later, 
he developed a red-violaceous lesion on the lower-arms, histologically
suggestive for Kaposi’s sarcoma (KS) (Figure 3A,3B); for which the
patient underwent to clinical and instrumental evaluations.
As known calciphylaxis (CPX) is a rare condition involving 
subcutaneous vascular calcification and cutaneous necrosis, mostly 
observed in patients with renal failure. However CPX may also 
appear in patients affected by polymyositis, Sjogren syndrome, Lupus 
Erythematosus systemicus, Sarcoidosis and rheumatoid arthritis, 
especially in children. Clinically CPX can present itself as subcutaneous 
nodules,  infiltrate plaques or purpuric-like and livedo-like plaques, 
while in the late stages necrotic ulcers (with a bizarre shape and severe 
pain) may be the main cutaneous manifestations. After the diagnosis, 
the percentage of death is around 50% (during the first year), often due 
to sepsis or organ failure. The reported frequency of malignancy in DM 
has varied from about 20% to 25%, and probably with more aggressive 
forms, in this view it can be considered a paraneoplastic manifestation, 
more frequent in gynecologic malignancy, nasopharyngeal, but also 
gastrointestinal and lung cancer, especially in patient more than 50 
years old. In our patient the lung cancer was in remission and no 
metastasis was found. Up to date, dermatomyositis (DM) has rarely been 
described to present as a drug- induced CPX, although a case of CPX 
with harbinger’s myopathy was described in 1992 by Edelstein et al. [1]. 
In fact in a small percentage of patients the cutaneous lesions are due 
to or are exacerbated by drugs, but never reported with chemotherapic 
agents. Our report shows similarities with a recent published paper, 
where it was reported a gemcitabine-induced radiation myositis in a 
patient with dermatomyositis. At this point we are not able to state 
which drug induced skin toxicity.
To the best of our knowledge, in literature there are only 3 reports 
describing iatrogenic Kaposi’s sarcoma (KS) in patients with DM [2-
6], after treatments with prednisolone, prednisone and azathioprine 
[2-5]. In all these cases KS developed after an immunosuppressive 
treatment, with a median time of 9 months (ranging between 1/2 
months and 30 months). In our patient KS appeared 6 weeks after the 
immunosuppressive treatment beginning.  In this regard KS should be 
seen as a result of the immunosuppressive treatment, concluding that 
KS, not usually associated with DM, can appear in this group of patients 
after an immunosuppressive treatment, with a faster onset time. The 
pathogenesis of the muscle disease is becoming better understood, 
but the cutaneous disease mechanisms remain enigmatic. Our patient 
was under carboplatin/gemcitabine/taxotere/bevacizumab regimen to 
treat the lung cancer, however, no similar skin toxicity has never been 
described in literature and is not possible to state which drug can be 
directly connected, therefore CPX could be explained as drug induced 
or as a paraneoplastic sign, which revealed in advance another tumour 
(i.d. KS).
This observation is important for rheumatologists, dermatologists 
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Figure 1: Clinical image Malar and facial dusky erythema associated to 
massive periorbital edema. Large erythematous lesions on the back, involving 
also the upper part of gluteus, with a pseudo-necrotic surface, sometimes with 
a yellowish colour
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Figure 2:  (a) Histologic findings [haematoxylin and Eosin 20x] Perivascular 
inflammatory cells in the dermis with increased dermal mucin (B) [Haematoxylin 
and Eosin 20x] Atrophic epidermis with vacuolar basal changes and myofiber 
necrosis.
(A) (B)
Figure 3: (A) [Haematoxylin and Eosin 10x]Fascicular spindle cells and 
vascular cleft filled with erythrocytes. Monomorphous endothelial cells with 
dense nuclei without mitoses (B) [10X] Positivity to HHV8
and oncologists, due to the association between malignancy 
and dermatomyositis and the common use of gemcitabine as a 
chemotherapeutic agent, showing also how a steroid treatment can lead 
to an improvement of the cutaneous and muscular symptomatology, 
but it can induce immune disregulation [7]. Assuming that prognosis is 
poor in oncologic patients, a careful evaluation of each patient should 
be part of their initial and follow-up assessments.
